PDSB

PDS Biotechnology Corporation

4.21 USD
+0.31 (+7.95%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

PDS Biotechnology Corporation stock is up 47.2% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 8 July’s closed higher than June.

About PDS Biotechnology Corporation

PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.